FIGURE

Fig. 4

ID

ZDB-FIG-220720-28

Publication

Garcia et al., 2022 - Agonists of prostaglandin E₂ receptors as potential first in class treatment for nephronophthisis and related ciliopathies

Other Figures

All Figure Page

Back to All Figure Page

Fig. 4

Effect of Taprenepag, an EP2 agonist, on the Nphp1^?/?-associated retinopathy. (A) Representative images of H&E staining of retina sections from P21-old Nphp1^+/+ and Nphp1^?/? mice treated every 3 d with vehicle (5% Solutol) or Taprenepag (18 mg/kg) from P6 to P21. (Scale bar, 50 �m.) (B) Quantification of ONL/OPL thickness ratio in retinas from P21 Nphp1^?/? mice treated with vehicle (n = 8) or Taprenepag (n = 9). Each dot represents one mouse. Bars indicate mean. (C) Scotopic ERG recordings of P21-old Nphp1^+/+ or Nphp1^?/? retinas upon vehicle or Taprenepag treatment. (D) Quantification of scotopic a- (Left) and b-wave (Right) amplitude versus stimulus intensity (log) in P21 Nphp1^?/? mice treated by vehicle (SOL, n = 6) or Taprenepag (n = 7). Mann?Whitney U test: *P < 0.05, ns: not significant. Dots indicate mean � SEM. INL, inner nuclear segment; IPL, inner plexiform layer; IS, inner segment; ONL, outer nuclear segment; OPL, outer plexiform layer; OS, outer segment; RPE, retinal pigmented epithelium; SOL, Solutol; TAP, Taprenepag.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Proc. Natl. Acad. Sci. USA